BIOMERICA, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.5M | $5.3M | $5.4M | $5.3M | $18.9M | $7.2M | $6.7M | $5.2M |
| Cost of Revenue | $4.1M | $4.8M | $4.8M | $4.9M | $15.9M | $6.8M | $5.0M | $3.9M |
| Gross Profit | $362.0K | $498.0K | $611.0K | $446.0K | $3.0M | $366.3K | $1.7M | $1.3M |
| Gross Margin | 8.1% | 9.4% | 11.3% | 8.4% | 15.8% | 5.1% | 26.0% | 24.8% |
| Operating Expenses | ||||||||
| Research & Development | $788.0K | $1.0M | $1.5M | $1.6M | $1.8M | $2.2M | $1.9M | $1.7M |
| SG&A Expense | $4.9M | $4.6M | $5.5M | $6.1M | $5.7M | $5.7M | $2.5M | $2.0M |
| Operating Income | $-5.3M | $-5.1M | $-6.4M | $-7.2M | $-4.5M | $-7.5M | $-2.7M | $-2.4M |
| Operating Margin | -119.5% | -96.7% | -117.6% | -135.3% | -24.0% | -104.2% | -41.0% | -46.4% |
| Interest Expense | — | — | — | — | — | $367 | $9 | $47 |
| Pretax Income | $-3.8M | $-5.0M | $-5.9M | $-7.1M | $-4.5M | $-7.4M | $-2.7M | $-2.4M |
| Income Tax Expense | $23.0K | $1.0K | $42.0K | $51.0K | $24.0K | $13.1K | $7.4K | $24.2K |
| Net Income | $-3.8M | $-5.0M | $-6.0M | $-7.1M | $-4.5M | $-7.4M | $-2.7M | $-2.4M |
| Net Margin | -84.8% | -93.6% | -110.4% | -133.7% | -24.0% | -103.4% | -40.0% | -46.0% |
| EPS (Basic) | $-1.30 | $-2.16 | $-2.84 | $-0.50 | $-0.36 | $-0.62 | $-0.26 | $-0.26 |
| EPS (Diluted) | $-1.30 | $-2.16 | $-2.84 | $-0.50 | $-0.36 | $-0.62 | $-0.26 | $-0.26 |
| Shares Outstanding (Basic) | 2.9M | 2.3M | 2.1M | 14.2M | 12.7M | 11.9M | 10.2M | 9.2M |
| Shares Outstanding (Diluted) | 2.9M | 2.3M | 2.1M | 14.2M | 12.7M | 11.9M | 10.2M | 9.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |